IFN-α2b and thalidomide synergistically inhibit tumor-induced angiogenesis

Journal of Interferon and Cytokine Research

Volumn 23, Issue 1, 2003, Pages 3-10

  Bauer, Joseph A ^a   Morrison, Bei H ^a   Grane, Ronald W ^a   Jacobs, Barbara S ^a   Borden, Ernest C ^a,b   Lindner, Daniel J ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUMAGILLOL CHLOROACETYLCARBAMATE; INTERFERON; MINOCYCLINE; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; THALIDOMIDE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DERMIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR; TUMOR GROWTH; XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; DRUG ADMINISTRATION; DRUG EFFECT; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; MALE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANIMALIA; MURINAE; MUS MUSCULUS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; POLYETHYLENE GLYCOLS; THALIDOMIDE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0037228273     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/10799900360520397     Document Type: Article

References (42)

1. FOLKMAN, J., MERLER, E., ABERNATHY, C., and WILLIAMS, G. (1971). Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 133, 275-288.
2. FOLKMAN, J. (1972). Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 175, 409-416.
3. GIMBRONE, M. A., Jr., LEAPMAN, S. B., COTRAN, R. S., and FOLKMAN, J. (1972). Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136, 261-276.
4. HANAHAN, D., and FOLKMAN, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.
5. BROUTY-BOYE, D., and ZETTER, B. R. (1980). Inhibition of cell motility by interferon. Science 208, 516-518.
6. SIDKY, Y. A., and BORDEN, E. C. (1987). Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyle-induced vascular responses. Cancer Res. 47, 5155-5161.
7. NORIOKA, K., MITAKA, T., MOCHIZUKI, Y., HARA, M., KAWAGOE, M., and NAKAMURA, H. (1994). Interaction of interleukin-1 and interferon-gamma on fibroblast growth factor-induced angiogenesis. Jpn. J. Cancer Res. 85, 522-529.
8. VOEST, E. E., KENYON, B. M., O'REILLY, M.S., TRUITT, G., D'AMATO, R.J., and FOLKMAN, J. (1995). Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87, 581-586.
9. D'AMATO, R. J., LOUGHNAN, M. S., FLYNM, E., and FOLKMAN, J. (1994). Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91, 4082-4085.
10. KENYON, B. M., BROWNE, F., and D'AMATO, R. J. (1997). Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 64, 971-978.
11. KRUSE, F. E., JOUSSEN, A. M., ROHRSCHNEIDER, K., BECKER, M. D., and VOLCKER, H. E. (1998). Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch. Clin. Exp. Opthalmol. 236, 461-466.
12. JOSEPH, I. B., and ISAACS, J. T. (1998). Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J. Natl. Cancer Inst. 90, 1648-1653.
13. SAUER, H., GUNTHER, J., HESCHELER, J., and WARTENBERG, M. (2000). Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. Am. J. Pathol. 156, 151-158.
14. LENTZSCH, S., ROGERS, M. S., LEBLANC, R., BIRSNER, A. E., SHAH, J. H., TRESTON, A. M., ANDERSON, K. C., and D'AMATO, R. J. (2002). S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res. 62, 2300-2305.
15. MOREIRA, A. L., FRIEDLANDER, D. R., SHIF, B., KAPLAN, G., and ZAGZAG, D. (1999). Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neurooncol. 43, 109-114.
16. JULIUSSON, G., CELSING, F., TURESSON, T, LENHOFF, S., ADRIANSSON, M., and MALM, C. (2000). Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J. Haematol. 109, 89-96.
17. RAJKUMAR, S. V., and WITZIG, T. E. (2000). A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat. Rev. 26, 351-362.
18. GARCIA-SANZ, R., GONZALEZ-FRAILE, M. I., SIERRA, M., LOPEZ, C., GONZALEZ, M., and SAN MIGUEL, J. F. (2002). The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol. J. 3, 43-48.
19. GAGLIARDI, A., and COLLINS, D. C. (1993). Inhibition of angiogenesis by antiestrogens. Cancer Res. 53, 533-535.
20. BLACKWELL K. L., HAROON, Z. A., SHAN, S., SAITO, W., BROADWATER, G., GREENBERG, C. S., and DEWHIRST, M. W. (2000). Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin. Cancer Res. 6, 4359-4364.
21. LINDNER, D. J., and BORDEN, E. C. (1997). Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis, Int. J. Cancer 71, 456-461.
22. WANG, Y. S., YOUNGSTER, S., BAUSCH, J., ZHANG, R., McNEMAR, C., and WYSS, D. F. (2000). Identilication of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 39, 10634-10640.
23. GLUE, P., FANG, J. W., ROUZIER-PANIS, R., RAFFANEL, C., SABO, R., GUPTA, S. K., SALFI, M., and JACOBS, S. (2000). Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther. 68, 556-567.
24. RUBINSTEIN, L. V., SHOEMAKER, R. H., PAULL, K. D., SIMON, R. M., TOSINI, S., SKEHAN, P., SCUDIERO, D. A., MONKS, A., and BOYD, M. R. (1990). Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 82, 1113-1118.
25. SKEHAN, P., STORENG, R., SCUDIERO, D., MONKS, A., McMAHON, J., VISTICA, D., WARREN, J. T., BOKESCH, H., KENNEY, S., and BOYD, M. R. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107-1112.
26. CHOU, T. C., and TALALAY, P. (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzymes Regul. 22, 27-55.
27. EZEKOWITZ, R. A. B., MILLIKEN, J. B., and FOLKMAN, J. (1992). Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med. 326, 1456-1463.
28. ORCHARD, P. J., SMITH, C. M., 3rd, WOODS, W. G., DAY, D. L., DEHNER, L. P., and SHAPIRO, R. (1989). Treatment of haemangioendotheliomas with alpha interferon. Lancet 2, 565-567.
29. MARLER, J. J., RUBIN, J. B., TREDE, N. S., CONNORS, S., GRIER, H., UPTON, J., MULLIKEN, J. B., and FOLKMAN, J. (2002). Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics 109, E37.
30. RIEDEL, F., GOTTE, K., BERGLER, W., ROJAS, W., and HORMANN, K. (2000). Expression of basic fibroblast growth factor protein and its down-regulation by interferons in head and neck cancer. Head Neck 22, 183-189.
31. SINGH, R. K., GUTMAN, M., BUCANA, C. D., SANCHEZ, R., LLANSA, N., and FIDLER, I. J. (1995). Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA 92, 4562-4566.
32. SLATON, J. W., PERROTTE, P., INOUE, K., DINNEY, C. P., and FIDLER, I. J. (1999). Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 5, 2726-2734.
33. NICHOLSON, S. E., and HILTON, D. J. (1998). The SOCS proteins: a new family of negative regulators of signal transduction. J. Leukocyte Biol. 63, 665-668.
34. NARAZAKI, M., FUJIMOTO, M., MATSUMOTO, T., MORITA, Y., SAITO, H., KAJITA, T., YOSHIZAKI, K., NAKA, T., and KISHIMOTO, T. (1998). Three distinct domains of SS1-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc. Natl. Acad. Sci. USA 95, 13130-13134.
35. LIU, B., LIAO, J., RAO, X., KUSHNER, S. A., CHUNG, C. D., CHANG, D. D., and SHUAI, K. (1998). Inhibition of Stat1-mediated gene activation by P1AS1. Proc. Natl. Acad. Sci. USA 95, 10626-10631.
36. BALKWILL, F. R., MOODIE, E. M., FREEDMAN, V., and FANTES, K. H. (1982). Human interferon inhibits the growth of established human breast tumours in the nude mouse. Int. J. Cancer 30, 231-235.
37. GRESSER, I., BELARDELLI, F., MAURY, C., TOVEY, M. G., and MAUNOURY, M. T. (1986). Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. IV. Definition of optimal treatment regimens. Int. J. Cancer 38, 251-257.
38. SHARMA, S., GHODDOUSSI, M., GAO, P., KELLOFF, G. J., STEELE, V. E., and KOPELOVICH, L. (2001). A quantitative angiogenesis model for efficacy testing of chemopreventive agents. Anticancer Res. 21, 3829-3837.
39. OR, R., FEFERMAN, R., and SHOSHAN, S. (1998). Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Exp. Hematol. 26, 217-221.
40. DAVIES, F. E., RAJE, N., HIDESHIMA, T., LENTZSCH, S., YOUNG, G., TAI, Y. T., LIN, B., PODAR, K., GUPTA, D., CHAUHAN, D., TREON, S. P., RICHARDSON, P. G., SCHLOSSMAN, R. L., MORGAN, G. J., MULLER, G. W., STIRLING, D. I. and ANDERSON, K. C. (2001). Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98, 210-216.
41. MINISCHETTI, M., VACCA, A., RIBATTI, D., IURLARO, M., RIA, R., PELLEGRINO, A., GASPARINI, G., and DAMMACCO, A. F. (2000). TNP-470 and recombinant human interferon-alpha2a inhibit angiogenesis synergistically. Br. J. Haematol. 109, 829-837.
42. PARANGI, S., O'REILLY, M., CHRISTOFORI, G., HOLMGREN, L., GROSFELD, J., FOLKMAN, J., and HANAHAN, D. (1996). Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA 93, 2002-2007.